10. Rituxan

Rituxan
Rituxan hit $6.54 billion in sales in 2019, putting it second behind colorectal cancer therapy Avastin in terms of sales for Roche's blockbuster oncology troika. (Roche)

Rituxan
Company: Roche
2019 sales: $6.54 billion
Projected 2026 sales: $1.84 billion
Projected CAGR: -17%
Used for: non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis and pemphigus vulgaris

With Roche's top three oncology meds facing biosimilar challengers in the U.S., the days of peak sales for at least two look to be coming to a rapid end. One of those, Rituxan, was the last of the three to face copycat challengers—but the damage could be dramatic in the coming years. 

Rituxan hit $6.54 billion in sales in 2019, putting it second behind colorectal cancer therapy Avastin in terms of sales for Roche's blockbuster oncology troika. With biosims already on the U.S. market, Evaluate Pharma predicts that Rituxan's sales could plummet to just $1.84 billion in 2026. 

Like copycats for both Avastin and Herceptin, U.S. biosimilars came after Rituxan in the back half of 2019. 

RELATED: Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S.

10. Rituxan

Suggested Articles

The next wave of immuno-oncology R&D includes drugs that interact with a wide range of emerging immune targets, including TIGIT and CD47.

Emerging targets like KRAS, MET and RET are inspiring novel kinase inhibitor development and fueling billions in pharma deals.

Despite the rise of cell therapies to treat cancer, R&D centered on novel tyrosine kinase inhibitors and immuno-oncology targets is booming.